BioPharma
CDMOs and Advanced Technologies in Biopharma Manufacturing
The biopharmaceutical sector is driven by rising global healthcare needs, technology, technological advancements, and the imperative to remain agile in a highly regulated environment. The need for increased efficiency, cost savings, and compressed timelines has resulted in the leading...
BioPharma
Biopharma Production with AI: A New Era in Manufacturing
A New Era of Biopharma Production with AI
The biopharma industry is undergoing a transformation as it capitalises on the potential of artificial intelligence (AI) to revolutionise production processes. Manufacturers are currently facing the most significant challenge in history: the...
BioPharma
Asia’s Bio Sovereignty: Nations Reclaiming Biologics Control
The biopharmaceutical industry in the Asia-Pacific area has seen a significant strategic shift in recent years; this trend is now commonly acknowledged as Asia's bio sovereignty movement. Countries like China, India, Japan, South Korea, and Singapore are making daring...
BioPharma
Digital Twins in Biomanufacturing: APAC’s Leap in Innovation
The Asia-Pacific (APAC) region is fast embracing biomanufacturing, leading-edge technology that is poised to redefine manufacturing processes and efficiency. One of the most revolutionary of these technologies is bringing digital twin technology into play. With the industry facing elevated...
BioPharma
AI Drug Discovery Transforming APAC Biopharma Innovation
The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by the tremendous progress made in artificial intelligence (AI). The use of AI technologies to drive drug discovery is not just a fad but a paradigm shift transforming the way new...
BioPharma
CDMO Market For Small Molecule Innovation Soars By 2033
It has been anticipated that the market for contract development and manufacturing organizations (CDMOs) that specialize in small molecule innovation would reach a value of $48.09 billion in 2023 and $89.43 billion in 2033. This information comes from several...
BioPharma
The Biopharma CDMO Market Surges With Outsourcing Growth
A recent study found that 86.9% of biopharmaceutical companies outsource at least some of their work. This has helped to build the $14 billion biopharmaceutical contract manufacturing business.
The researchers forecast a highly promising and profitable future for biopharmaceutical contract...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read